Drug Development · global
From Pain Relief to Kidney Protection: Oral Fabry Disease Drug Enters Phase 3 Trial as Nxera Secures Rights in Parts of Asia
Lucerastat previously failed to demonstrate relief of neuropathic pain. Now, kidney biopsies will test its ability to reduce lipid accumulation. A new trial and an Asian licensing partnership are moving development forward, but whether it can protect kidney function still requires clinical evidence.
For patients with Fabry disease, the threat extends beyond pain to kidney damage that accumulates year after year. Lucerastat, an oral drug candidate that previously suffered a setback in a pain trial, is now shifting its evaluation toward the kidneys. On October 28, Idorsia announced the launch of the Phase 3 FAB-KLEAR trial and signed a co-development and commercialization agreement with Nxera Pharma, bringing in a regional partner for the therapy, which has not yet received marketing approval.
Fabry disease is a rare inherited lysosomal storage disorder. Variants in the GLA gene leave patients with insufficient α-galactosidase A activity, allowing a lipid called Gb3 to accumulate in cells and damage the kidneys, heart, and nervous system. Lucerastat uses a “substrate reduction” strategy, inhibiting glucosylceramide synthase to reduce the production of related lipids at the source. Its mechanism of action also gives researchers hope that it may be suitable for patients with different GLA variants.
FAB-KLEAR plans to enroll 16 adult men who have never received Fabry-specific treatment or have discontinued such treatment for at least six months. The open-label study will compare kidney biopsies taken before treatment and at month 18, primarily examining changes in scores for Gb3 deposits in peritubular capillaries. It will also assess plasma Gb3, safety, and pharmacokinetics. Its first question is whether the drug can reduce the lipid burden in kidney tissue.
This shift is supported by research findings, but gaps remain to be addressed. Results from the Phase 3 MODIFY trial and its extension study, published this year in Nature Communications, showed that lucerastat did not meet its primary endpoint of reducing neuropathic pain at six months. Although Gb3 levels fell in blood and urine, the plasma Gb3 results remained subject to hierarchical statistical testing and could not be considered formally statistically significant after the primary endpoint failed. The extension study also showed a signal of slower kidney function decline, but this came from comparisons with patients’ own pretreatment data and is not yet sufficient to establish a kidney-protective effect.
Reducing deposits in tissue and preserving patients’ kidney function over the long term remain distinct questions. FAB-KLEAR is small, enrolls only a specific group of adult men, and uses participants’ own baseline measurements for comparison. These limitations must be considered when interpreting its results. The overall Phase 3 program also includes the planned 74-participant FAB-SWITCH trial, which will compare kidney function outcomes with lucerastat and standard enzyme replacement therapy, providing more direct evidence from a treatment comparison.
The partnership also shares the funding requirements for further development. Orrick, which served as Nxera’s legal adviser on the transaction, confirmed that the license covers Japan, South Korea, Taiwan, and certain other Asia-Pacific markets, excluding China. Nxera will pay CHF 7 million upfront and contribute to the global Phase 3 program, while Idorsia will be eligible to receive royalties on net sales in the licensed territories. These rights stem from an option Nxera obtained when it acquired Idorsia’s Asia-Pacific business outside China in 2023, which it has now formally exercised.
Idorsia said its Phase 3 development strategy has been aligned with the U.S. Food and Drug Administration and is consistent with earlier feedback from the European Medicines Agency, with the aim of submitting a marketing application as early as 2029. That timeline remains dependent on trial results. For patients, the next crucial development is whether kidney biopsies and the comparative trial can together demonstrate that reducing lipid accumulation translates into lasting kidney protection.